Steve Balsis1, Lisa Geraci1, Jared Benge2, Deborah A Lowe1, Tabina K Choudhury1, Robert Tirso1, Rachelle S Doody3. 1. Department of Psychological and Brain Sciences, Texas A&M University, College Station. 2. Baylor Scott and White Neurosciences Institute, Temple, Texas. 3. Department of Neurology, Baylor College of Medicine, Alzheimer's Disease and Memory Disorders Center, Houston, Texas.
Abstract
Objectives: Alzheimer's disease (AD) is a progressive disease reflected in markers across assessment modalities, including neuroimaging, cognitive testing, and evaluation of adaptive function. Identifying a single continuum of decline across assessment modalities in a single sample is statistically challenging because of the multivariate nature of the data. To address this challenge, we implemented advanced statistical analyses designed specifically to model complex data across a single continuum. Method: We analyzed data from the Alzheimer's Disease Neuroimaging Initiative (ADNI; N = 1,056), focusing on indicators from the assessments of magnetic resonance imaging (MRI) volume, fluorodeoxyglucose positron emission tomography (FDG-PET) metabolic activity, cognitive performance, and adaptive function. Item response theory was used to identify the continuum of decline. Then, through a process of statistical scaling, indicators across all modalities were linked to that continuum and analyzed. Results: Findings revealed that measures of MRI volume, FDG-PET metabolic activity, and adaptive function added measurement precision beyond that provided by cognitive measures, particularly in the relatively mild range of disease severity. More specifically, MRI volume, and FDG-PET metabolic activity become compromised in the very mild range of severity, followed by cognitive performance and finally adaptive function. Conclusion: Our statistically derived models of the AD pathological cascade are consistent with existing theoretical models.
Objectives:Alzheimer's disease (AD) is a progressive disease reflected in markers across assessment modalities, including neuroimaging, cognitive testing, and evaluation of adaptive function. Identifying a single continuum of decline across assessment modalities in a single sample is statistically challenging because of the multivariate nature of the data. To address this challenge, we implemented advanced statistical analyses designed specifically to model complex data across a single continuum. Method: We analyzed data from the Alzheimer's Disease Neuroimaging Initiative (ADNI; N = 1,056), focusing on indicators from the assessments of magnetic resonance imaging (MRI) volume, fluorodeoxyglucose positron emission tomography (FDG-PET) metabolic activity, cognitive performance, and adaptive function. Item response theory was used to identify the continuum of decline. Then, through a process of statistical scaling, indicators across all modalities were linked to that continuum and analyzed. Results: Findings revealed that measures of MRI volume, FDG-PET metabolic activity, and adaptive function added measurement precision beyond that provided by cognitive measures, particularly in the relatively mild range of disease severity. More specifically, MRI volume, and FDG-PET metabolic activity become compromised in the very mild range of severity, followed by cognitive performance and finally adaptive function. Conclusion: Our statistically derived models of the AD pathological cascade are consistent with existing theoretical models.
Authors: D P Devanand; Ravi Bansal; Jun Liu; Xuejun Hao; Gnanavalli Pradhaban; Bradley S Peterson Journal: Neuroimage Date: 2012-01-25 Impact factor: 6.556
Authors: Kewei Chen; Jessica B S Langbaum; Adam S Fleisher; Napatkamon Ayutyanont; Cole Reschke; Wendy Lee; Xiaofen Liu; Dan Bandy; Gene E Alexander; Paul M Thompson; Norman L Foster; Danielle J Harvey; Mony J de Leon; Robert A Koeppe; William J Jagust; Michael W Weiner; Eric M Reiman Journal: Neuroimage Date: 2010-03-02 Impact factor: 6.556
Authors: Rahul S Desikan; Mert R Sabuncu; Nicholas J Schmansky; Martin Reuter; Howard J Cabral; Christopher P Hess; Michael W Weiner; Alessandro Biffi; Christopher D Anderson; Jonathan Rosand; David H Salat; Thomas L Kemper; Anders M Dale; Reisa A Sperling; Bruce Fischl Journal: PLoS One Date: 2010-09-23 Impact factor: 3.240
Authors: J C Morris; A Heyman; R C Mohs; J P Hughes; G van Belle; G Fillenbaum; E D Mellits; C Clark Journal: Neurology Date: 1989-09 Impact factor: 9.910
Authors: Rachael I Scahill; Jonathan M Schott; John M Stevens; Martin N Rossor; Nick C Fox Journal: Proc Natl Acad Sci U S A Date: 2002-04-02 Impact factor: 11.205
Authors: Joshua T Fuller; Tabina K Choudhury; Deborah A Lowe; Steve Balsis Journal: J Gerontol B Psychol Sci Soc Sci Date: 2020-10-16 Impact factor: 4.077
Authors: Dallas P Veitch; Michael W Weiner; Paul S Aisen; Laurel A Beckett; Charles DeCarli; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Susan M Landau; John C Morris; Ozioma Okonkwo; Richard J Perrin; Ronald C Petersen; Monica Rivera-Mindt; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; Duygu Tosun; John Q Trojanowski Journal: Alzheimers Dement Date: 2021-09-28 Impact factor: 16.655